Chinese Japanese Germany Korea


Abarelix structure
Chemical Name:
R 3827;PPI-149;Plenaxis;Abarelix;Abarelix Acetate;Abarelix Acetate(Plenaxis);Abarelix,R3827,PPI 149, >98%;Ac-DNal-DCpa-DPal-Ser-NαMeTyr-DAsp-Leu-Ilys-Pro-DAl-NH2;D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-
Molecular Formula:
Formula Weight:
MOL File:

Abarelix Properties

Boiling point:
1688.4±65.0 °C(Predicted)
1.286±0.06 g/cm3(Predicted)
NCI Dictionary of Cancer Terms
abarelix; Plenaxis

Abarelix Chemical Properties,Uses,Production


Abarelix is an antagonist of the gonadotropin releasing-hormone (Gn RH) receptor, and it was launched as an intramuscular injection for the palliative treatment of advanced symptomatic prostate cancer. Hormonal therapy of prostate cancer is based on the modulation of testosterone to achieve medical castration levels. The inhibition of GnRH activity causes the suppression of luteinizing hormone (LH) and follicle stimulating hormone (FSH) secretion, thereby reducing the secretion of testosterone by the testes. Abarelix is the first GnRH antagonist to reach its market. Hormonal therapy with GnRH agonists such as leuprolide, buserelin, and goserelin has been in use for over two decades. Drugs of this type achieve the suppression of LH and FSH by a feedback inhibition mechanism, which involves an initial rise in the LH and FSH levels and, consequently, in the levels of testosterone. A testosterone surge may induce a clinical tumor flare that worsens cancer-related symptoms. This phenomenon is observed in 4–33% of patients receiving a GnRH agonist. A GnRH antagonist such as abarelix acts by direct inhibition of LH and FSH secretion, which avoids the initial surge in serum testosterone concentrations. Abarelix is a decapeptide, and it is prepared by a typical coupling cycle for peptide synthesis using Boc-amino acids and a methylbenzhydrylamine (MBHA) resin. Abarelix has high binding affinity for GnRH receptor (Kd=0.1 nM). Following intramuscular administration of a 100 mg dose, abarelix is absorbed slowly with a Cmax of 43.4 ng/mL observed approximately 3 days after the injection and has a half-life of about 13 days. The apparent volume of distribution is over 4000 L, suggesting extensive distribution. Abarelix has high protein binding (96–99%), and it is primarily metabolized via hydrolysis of peptide bonds. Following a dose of 15 μg/kg in humans, approximately 13% of abarelix is recovered unchanged in the urine, with no detectable metabolites. The renal clearance of abarelix is 14.4 L/day following a 100 mg dose. Two randomized, open label, comparative clinical trials involving 348 patients demonstrated the efficacy of abarelix versus a GnRH agonist (leuprolide) as well as a combination of GnRH agonist and anti-androgen (leuprolide+bicalutamide). In these trials, both abarelix and the comparators reduced testosterone to medical castration levels (<50 ng/dL) by day 29 of therapy in 94–98% of the patients. However, a significant difference was observed between the two groups for the occurrence of testosterone surge (0% in the abarelix group versus 82% in the GnRH agonist group) and for the rapidity of attaining castration levels (72% versus 0% on day 8 in the abarelix and GnRH agonist groups, respectively). Both groups maintained medical castration levels of testosterone with similar efficacy between days 29 and 85 of treatment. Abarelix was generally well tolerated in these trials. Approximately 3% of the patients experienced an immediate-onset allergic reaction. Other adverse events were similar to comparator controls and included hot flushes, sleep disturbance, pain, and breast enlargement. The recommended dosage of abarelix is 100 mg intramuscular injection on days 1, 15, and 29 of therapy, and every 4 weeks thereafter.


Praecis (US)


Gonad-stimulating principle; antagonist (LHRH).


ChEBI: A polypeptide compound composed of ten natural and non-natural amino acid resiudes in a linear sequence.

brand name

Plenaxis (Praecis).

Abarelix Preparation Products And Raw materials

Raw materials

Preparation Products

Abarelix Suppliers

Global( 85)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Alpha Biopharmaceuticals Co., Ltd
0086-411-39042693 China 921 58
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 21821 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 22626 55
career henan chemical co
+86-371-86658258 CHINA 30045 58
Chengdu Biopurify Phytochemicals Ltd.
18080483897 CHINA 2645 58
Shaanxi Pioneer Biotech Co., Ltd .
029-84385017 CHINA 3000 58
Hubei xin bonus chemical co. LTD
027-59338440 CHINA 23045 58
Chongqing Chemdad Co., Ltd
+86-13650506873 CHINA 35434 58
Alchem Pharmtech,Inc.
8485655694 United States 63728 58
Cellmano Biotech Limited
+86-551-65326641 CHINA 1044 58

View Lastest Price from Abarelix manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2019-07-04 Abarelix
US $1.00 / KG 1KG 98% 1kg,5kg,100kg career henan chemical co

183552-38-7(Abarelix)Related Search:

  • Abarelix,R3827,PPI 149, >98%
  • PPI-149
  • Abarelix Acetate
  • Abarelix
  • Plenaxis
  • R 3827
  • Ac-DNal-DCpa-DPal-Ser-NαMeTyr-DAsp-Leu-Ilys-Pro-DAl-NH2
  • Abarelix Acetate(Plenaxis)
  • D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-
  • 183552-38-7
  • C72H95ClN14O14
Copyright 2017 © ChemicalBook. All rights reserved